Full-Time

Associate Director

Business Development Transactions

Posted on 4/15/2025

Merck

Merck

10,001+ employees

Develops medicines and vaccines for health

No salary listed

Senior

No H1B Sponsorship

London, UK

Hybrid work arrangements are available, indicating a mix of in-office and remote work.

Category
Business Development
Business & Strategy
Requirements
  • Bachelor’s degree in a scientific discipline; an advanced degree in business, law or science is a plus.
  • A minimum of 5 years work experience in one or more pharmaceutical or biotech companies.
  • Experience in transactions with academic institutions; contract drafting and negotiation experience desired.
  • Understanding of scientific principles and the drug-development process.
  • Candidate must demonstrate superb interpersonal skills and the ability to influence without authority.
  • Exceptional written, verbal, and organizational skills are essential.
Responsibilities
  • Collaborate closely with our company's research scientists, management, legal and external partners to negotiate material transfers, licenses, evaluations, consortia, research collaborations and other agreements to establish external scientific partnerships.
  • Negotiate with external counterparts to execute appropriate agreements in a timely manner in support of our Research Division objectives and compliance policies.
  • Educate and influence our Research Division scientists and management in the executional and relational aspects of external partnering.
  • Participate and network at industry-academia professional events to establish our Research Division as a partner of choice.
Desired Qualifications
  • An advanced degree in business, law or science is a plus.

Merck develops medicines and vaccines to address significant health challenges such as cardiovascular disease, diabetes, and cancer. The company conducts extensive research and development to create new treatments, focusing on the pharmaceutical and biotechnology sectors. Merck generates revenue through the sale of prescription medications, vaccines, and animal health products. A key aspect of Merck's approach is its commitment to patient assistance, providing free medicines and vaccines to eligible individuals, as well as offering professional resources through platforms like Merck Connect and Merck Manuals. What sets Merck apart from its competitors is its strong emphasis on scientific research and its diverse range of healthcare solutions aimed at improving global health.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck's $1 billion investment strengthens U.S. vaccine manufacturing capabilities.
  • Oral peptide delivery systems could revolutionize peptide drug administration.
  • Kinase inhibitors expand Merck's R&D into autoimmune and neurodegenerative diseases.

What critics are saying

  • Increased competition from AstraZeneca and Novo Nordisk threatens Merck's market share.
  • Data privacy challenges may impact trust in Merck's AI healthcare collaboration.
  • Operational risks and regulatory hurdles may delay new vaccine manufacturing site.

What makes Merck unique

  • Merck's R&D focuses on innovative medicines for cardiovascular, diabetes, and cancer.
  • Merck's collaboration with Microsoft integrates AI to enhance clinical decision-making.
  • Merck's acquisition of Hengrui Pharma's Lp(a) inhibitor diversifies its cardiovascular portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Holidays

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Flexible Work Hours

Company News

BioSpace
Apr 15th, 2025
Merck Eyes Oral Peptide Delivery With Cyprumed Deal Worth up to $493M

Merck on Tuesday entered into a nonexclusive licensing and option pact with Austrian biotech Cyprumed in a bid to make its peptide drugs orally available.

PR Newswire
Apr 14th, 2025
Merck Manuals To Collaborate With Microsoft To Integrate Medical Information Resources Into Healthcare Agent Service In Microsoft Copilot Studio

RAHWAY, N.J., April 14, 2025 /PRNewswire/ -- The Merck Manuals is pleased to announce its collaboration with Microsoft to integrate its esteemed professional medical reference into healthcare agent service in Microsoft Copilot Studio. This exciting initiative harnesses the power of Generative AI (GenAI) to provide clinicians with trusted, comprehensive, and evidence-based medical content at the point of care.The Merck Manuals is proud to be an independent (non-government) medical information resource integrated into this platform. This collaboration exemplifies a commitment to enhancing clinical workflows by incorporating Merck Manuals' authoritative content into Microsoft's healthcare agent service in Copilot Studio. This integration empowers healthcare technology developers to create generative AI-driven healthcare agents that leverage this high-value content to grant clinicians immediate access to vital medical information."Clinicians and healthcare organizations worldwide depend on the Merck Manuals and MSD Manuals for accurate and reliable answers to their clinical questions," stated Dr. Sandy Falk, Editor-in-Chief of the Merck Manuals. "Through this collaboration with Microsoft, we are building solutions to deliver our comprehensive, evidence-based content to meet the needs of healthcare professionals

APP
Apr 14th, 2025
Novartis plans $23B expansion of manufacturing in US, including North Jersey site

Merck announced plans to spend $1 billion on a vaccine manufacturing site in North Carolina, plus $8 billion on other upgrades.

PRWeb
Apr 12th, 2025
The Melanoma Research Foundation To Host The Dc Miles For Melanoma 5K

The Melanoma Research Foundation (MRF) is thrilled to announce one of the first events in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual DC event on Saturday, May 3, 2025 at Yards Park at 7:30 AM ET. Opening Ceremonies will start at 8:30 AM ET and our race will kick off promptly at 9:00 AM ET. We are excited to share that Ian Michael Crumm, Celebrity Esthetician, will be joining us on event day as our emcee!WASHINGTON, April 12, 2025 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) is thrilled to announce one of the first events in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual DC event on Saturday, May 3, 2025 at Yards Park at 7:30 AM ET. Opening Ceremonies will start at 8:30 AM ET and our race will kick off promptly at 9:00 AM ET

Markets Gone Wild
Apr 2nd, 2025
Merck & Co., Inc. Investors: Unlocking Value with Levi and Korsinsky - A Must-Read for Shareholders!

The dedicated securities fraud team at Zamansky LLC (ZLK) is here to help you understand your legal rights and potential recovery options under the federal securities laws.